With an income increase of 2203.05% in the second quarter 2026, year on year to cumulative value of $19 million, and with 226 employees, Protalix Biotherapeutics Inc 's income per employee grew on trailing twelve month basis to $ 83,827. The income per employee at Protalix Biotherapeutics Inc ' was above the company average.
The Healthcare sector has seen employees of 17 other companies achieving higher income per employee. While Protalix Biotherapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 1181 to 1183.

What is Income per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Net Income per Employee▼

None ▼

Net Income per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

PLX Net Income per Employee	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Net Income Change	2203.05 %	-	-	-27.22 %	-
Net Income per Employee (TTM) $	83,827	67,841	-29,221	23,867	27,765
PLX's Total Ranking	# 1183	# 1181	# 2489	# 977	# 745
Seq. Net Income Change	-79.38 %	-	-	1335.98 %	-

PLX Company Profile >> Back to PLX Efficiency Comparisons >> Compare PLX Net Income per Employee to its Competitors

PLX Net Income per Employee Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 18
Healthcare Sector	# 105
Overall Market	# 1183

Net Income per Employee Statistics
High	Average	Low
$ 256,801	$ -67,610	$ -353,606
(Dec 31 2015)		(Mar 31 2017)

Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector	Income per Employee	Income 12 month ending Jun 30 2026	Number of Employees Jun 30 2026
Iradimed Corporation	138,883.19	$ 23.055 Million	166
Resmed Inc	133,974.76	$ 1,523.293 Million	11,370
Community Health Systems Inc	132,258.06	$ 410.000 Million	3,100
Collegium Pharmaceutical Inc	113,274.23	$ 47.915 Million	423
Ani Pharmaceuticals Inc	109,895.88	$ 106.599 Million	970
Entera Bio Ltd	109,500.00	$ 2.409 Million	22
Idexx Laboratories Inc	103,605.09	$ 1,139.656 Million	11,000
Progyny Inc	91,860.98	$ 78.633 Million	856
Globus Medical Inc	89,238.50	$ 535.431 Million	6,000
Protalix Biotherapeutics inc	83,827.43	$ 18.945 Million	226
Agilent Technologies inc	79,558.01	$ 1,440.000 Million	18,100
Alpha Pro Tech Ltd	79,325.20	$ 9.757 Million	123
Medpace Holdings Inc	79,274.19	$ 491.500 Million	6,200
Aveanna Healthcare Holdings Inc	78,503.43	$ 274.762 Million	3,500
Corcept Therapeutics Inc	74,261.64	$ 54.211 Million	730
Solventum Corporation	71,700.00	$ 1,434.000 Million	20,000
Strata Critical Medical Inc	66,923.46	$ 40.221 Million	601
Stryker Corp	66,589.29	$ 3,729.000 Million	56,000
Pro dex Inc	66,320.39	$ 13.662 Million	206
Edwards Lifesciences Corporation	62,725.00	$ 1,003.600 Million	16,000
Bio techne Corp	60,620.67	$ 181.862 Million	3,000
Msa Safety Inc	59,246.98	$ 314.009 Million	5,300
Pfizer Inc	58,266.67	$ 4,370.000 Million	75,000
Sbc Medical Group Holdings Incorporated	57,479.19	$ 49.605 Million	863
Electromed Inc	57,365.48	$ 11.301 Million	197
Utah Medical Products Inc	57,300.55	$ 10.486 Million	183
Livanova Plc	57,137.27	$ 188.553 Million	3,300
Medtronic Plc	55,463.16	$ 5,269.000 Million	95,000
Beone Medicines Ltd	54,642.25	$ 655.707 Million	12,000
Mettler toledo International Inc	54,554.88	$ 905.611 Million	16,600

Date modified: 2026-09-04T10:37:32+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.